Veliparib Facing Phase III Test in BRCA-Positive Breast Cancer
January 12th 2017Researchers are seeking to determine whether adding the PARP inhibitor veliparib to a chemotherapy combination will improve outcomes for patients with HER2-negative, germline BRCA-associated metastatic or locally advanced breast cancer.
When Values Collide: The Individual Versus the Common Good
January 9th 2017It is perhaps a little unusual that an oncol­ogy commentary would begin with a highly provocative discussion about the future of driverless cars, but there are similarities in the sharp corners of the debate over this new tech­nology and emerging trends in cancer care.